{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:51:59Z","timestamp":1791899519684,"version":"4.3.4"},"reference-count":73,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.mcna.2021.05.016","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T04:37:01Z","timestamp":1631075821000},"page":"1117-1134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":213,"title":["Update on Osteoporosis Screening and Management"],"prefix":"10.1016","volume":"105","author":[{"given":"Anika K.","family":"Anam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Insogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2021.05.016_bib1","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","article-title":"Diagnosis of osteoporosis and assessment of fracture risk","volume":"359","author":"Kanis","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2021.05.016_bib2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1359\/jbmr.1998.13.12.1915","article-title":"Bone density and fracture risk in men","volume":"13","author":"Melton","year":"1998","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.mcna.2021.05.016_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bone.2016.03.006","article-title":"Epidemiology of fractures in the United Kingdom 1988-2012: Variation with age, sex, geography, ethnicity and socioeconomic status","volume":"87","author":"Curtis","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.mcna.2021.05.016_bib4","series-title":"Osteoporosis: diagnosis, prevention, therapy","author":"Bartl","year":"2009"},{"key":"10.1016\/j.mcna.2021.05.016_bib5","first-page":"1522","article-title":"Effects of Age and Estrogen Status on Serum Parathyroid Hormone Levels and Biochemical Markers of Bone Turnover in Women: A Population-Based Study","volume":"82","author":"Khosla","year":"1997","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.mcna.2021.05.016_bib6","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.mcna.2021.05.016_bib8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","article-title":"Assessment of fracture risk","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.mcna.2021.05.016_bib9","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jocd.2013.08.003","article-title":"The Official Positions of the International Society for Clinical Densitometry: vertebral fracture assessment","volume":"16","author":"Rosen","year":"2013","journal-title":"J\u00a0Clin Densitom"},{"key":"10.1016\/j.mcna.2021.05.016_bib10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1373\/clinchem.2016.259085","article-title":"Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease","volume":"63","author":"Greenblatt","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.mcna.2021.05.016_bib11","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1359\/jbmr.1999.14.5.792","article-title":"Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices","volume":"14","author":"Woitge","year":"1999","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.mcna.2021.05.016_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S8756-3282(02)00791-3","article-title":"Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting","volume":"31","author":"Qvist","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.mcna.2021.05.016_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","article-title":"The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know","volume":"96","author":"Ross","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.mcna.2021.05.016_bib14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2265.2009.03701.x","article-title":"Reducing fracture risk with calcium and vitamin D","volume":"73","author":"Lips","year":"2010","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.mcna.2021.05.016_bib15","doi-asserted-by":"crossref","first-page":"e1917789","DOI":"10.1001\/jamanetworkopen.2019.17789","article-title":"Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis","volume":"2","author":"Yao","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.mcna.2021.05.016_bib16","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/009127000004001108","article-title":"Pharmacokinetic and pharmacodynamic comparison of two calcium supplements in postmenopausal women","volume":"40","author":"Heller","year":"2000","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.mcna.2021.05.016_bib17","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1210\/jc.2013-1516","article-title":"Calcium and vitamin D intake and mortality: results from the Canadian Multicentre Osteoporosis Study (CaMos)","volume":"98","author":"Langsetmo","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.mcna.2021.05.016_bib18","doi-asserted-by":"crossref","first-page":"856","DOI":"10.7326\/M16-1165","article-title":"Calcium Intake and Cardiovascular Disease Risk: An Updated Systematic Review and Meta-analysis","volume":"165","author":"Chung","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2021.05.016_bib19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/07315724.2019.1681202","article-title":"Calcium Supplementation and Coronary Artery Disease: A Methodological Confound?","volume":"39","author":"Wallace","year":"2020","journal-title":"J\u00a0Am Coll Nutr"},{"key":"10.1016\/j.mcna.2021.05.016_bib20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1359\/jbmr.081209","article-title":"Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective","volume":"24","author":"Kuchuk","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.mcna.2021.05.016_bib21","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.amjmed.2003.12.029","article-title":"Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults","volume":"116","author":"Bischoff-Ferrari","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.mcna.2021.05.016_bib22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/jbmr.1828","article-title":"Serum 25-hydroxyvitamin D and risk of major osteoporotic fractures in older U.S. adults","volume":"28","author":"Looker","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.mcna.2021.05.016_bib23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.7326\/0003-4819-149-4-200808190-00005","article-title":"Serum 25-hydroxyvitamin D concentrations and risk for hip fractures","volume":"149","author":"Cauley","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2021.05.016_bib24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1359\/JBMR.040208","article-title":"Dietary protein intake and risk of osteoporotic hip fracture in elderly residents of Utah","volume":"19","author":"Wengreen","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.mcna.2021.05.016_bib25","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1359\/jbmr.2000.15.12.2504","article-title":"Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study","volume":"15","author":"Hannan","year":"2000","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.mcna.2021.05.016_bib26","first-page":"1052","article-title":"Changes in bone turnover in young women consuming different levels of dietary protein","volume":"84","author":"Kerstetter","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.mcna.2021.05.016_bib27","first-page":"CD000333","article-title":"Exercise for preventing and treating osteoporosis in postmenopausal women","author":"Howe","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mcna.2021.05.016_bib28","first-page":"664","article-title":"Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention","volume":"49","year":"2001","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.mcna.2021.05.016_bib29","first-page":"f6234","article-title":"The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials","volume":"347","author":"El-Khoury","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.mcna.2021.05.016_bib30","article-title":"Interventions for preventing falls in older people living in the community","author":"Gillespie","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mcna.2021.05.016_bib31","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture Prevention with Zoledronate in Older Women with Osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.05.016_bib32","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.05.016_bib33","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: mechanisms of action","volume":"97","author":"Rodan","year":"1996","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.mcna.2021.05.016_bib34","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in\u00a0vitro and in\u00a0vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.mcna.2021.05.016_bib35","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: Mechanism of Action and Role in Clinical Practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.mcna.2021.05.016_bib36","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1542\/peds.2006-2023H","article-title":"Bisphosphonates: Mode of Action and Pharmacology","volume":"119","author":"Russell","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.mcna.2021.05.016_bib37","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2021.05.016_bib38","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.mcna.2021.05.016_bib39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of Risedronate on the Risk of Hip Fracture in Elderly Women","volume":"344","author":"McClung","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.05.016_bib40","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2021.05.016_bib41","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.05.016_bib42","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","article-title":"Characterization of and risk factors for the acute-phase response after zoledronic acid","volume":"95","author":"Reid","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.mcna.2021.05.016_bib43","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.mcna.2021.05.016_bib44","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.mcna.2021.05.016_bib45","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","article-title":"Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution","volume":"89","author":"Goh","year":"2007","journal-title":"J\u00a0Bone Joint Surg Br"},{"key":"10.1016\/j.mcna.2021.05.016_bib46","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.05.016_bib47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.mcna.2021.05.016_bib48","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","article-title":"Continuing Bisphosphonate Treatment for Osteoporosis \u2014 For Whom and for How Long?","volume":"366","author":"Black","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.05.016_bib49","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2021.05.016_bib50","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2021.05.016_bib51","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2021.05.016_bib52","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.mcna.2021.05.016_bib53","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/M14-0317","article-title":"Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review","volume":"161","author":"Crandall","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2021.05.016_bib54","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/archinte.164.8.871","article-title":"A\u00a0comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women","volume":"164","author":"Reid","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mcna.2021.05.016_bib55","doi-asserted-by":"crossref","first-page":"E189","DOI":"10.1210\/jc.2013-1707","article-title":"Effects of bazedoxifene\/conjugated estrogens on the endometrium and bone: a randomized trial","volume":"99","author":"Pinkerton","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.mcna.2021.05.016_bib56","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.05.016_bib57","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.mcna.2021.05.016_bib58","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.mcna.2021.05.016_bib59","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","article-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","volume":"23","author":"Watts","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.mcna.2021.05.016_bib60","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1210\/clinem\/dgz322","article-title":"Risk for Infections During Treatment With Denosumab for Osteoporosis: A Systematic Review and Meta-analysis","volume":"105","author":"Diker-Cohen","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.mcna.2021.05.016_bib61","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A\u00a0randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.mcna.2021.05.016_bib62","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/bmj.305.6853.556","article-title":"Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study","volume":"305","author":"Overgaard","year":"1992","journal-title":"Br Med J"},{"key":"10.1016\/j.mcna.2021.05.016_bib63","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/17453674.1997.11744761","article-title":"Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study","volume":"275","author":"Lyritis","year":"1997","journal-title":"Acta Orthop Scand Suppl"},{"key":"10.1016\/j.mcna.2021.05.016_bib64","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00198-015-3339-z","article-title":"Does salmon calcitonin cause cancer? A review and meta-analysis","volume":"27","author":"Wells","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.mcna.2021.05.016_bib65","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial","volume":"33","author":"Geusens","year":"2018","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.mcna.2021.05.016_bib66","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical Practice. Postmenopausal Osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.05.016_bib67","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1007\/s00198-018-4604-8","article-title":"The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years","volume":"29","author":"Gilsenan","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.mcna.2021.05.016_bib68","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2021.05.016_bib69","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1530\/JME-18-0176","article-title":"Novel actions of sclerostin on bone","volume":"62","author":"Holdsworth","year":"2019","journal-title":"J\u00a0Mol Endocrinol"},{"key":"10.1016\/j.mcna.2021.05.016_bib70","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.mcna.2021.05.016_bib71","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.05.016_bib72","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.05.016_bib73","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1759720X18785539","article-title":"Improving drug adherence in osteoporosis: an update on more recent studies","volume":"10","author":"Jaleel","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.mcna.2021.05.016_bib74","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","article-title":"Treatment failure in osteoporosis","volume":"23","author":"Diez-Perez","year":"2012","journal-title":"Osteoporos Int"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712521000857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712521000857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:46:15Z","timestamp":1758419175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712521000857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0025712521000857"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2021.05.016","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Osteoporosis Screening and Management","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2021.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}